Cozen O’Connor: The Trans-Pacific Partnership and Its Effect On Biosimilars [Inside Counsel]

The Trans-Pacific Partnership and Its Effect On Biosimilars [Inside Counsel]

Aaron Lukas and Keri Schaubert, associates of Cozen O’Connor’s IP group, discuss the effect that the Trans-Pacific Partnership will have on the biopharmaceutical and biosimilar industry. The Trans-Pacific Partnership is expected to face a tough battle in Congress, with exclusivity for biologic drugs a key concern for making of the law makers.  Once the TTP is passed, American biopharmaceutical companies will have greater protection in the overseas markets and patients will benefit from the introduction of biosimilar products whose exclusivity has expired. 

To read more click here.


Related Attorneys

Aaron Lukas, Ph.D.

Member

alukas@cozen.com

(202) 912-4823

Keri L. Schaubert, Ph.D.

Associate

kschaubert@cozen.com

(212) 883-2258


Related Practices